KPV Peptide: Anti-Inflammatory Uses, Evidence and Regulatory Status

KPV is a tripeptide made of three amino acids, lysine, proline and valine, which is where its name comes from. It is the C-terminal fragment occupying positions 11 to 13 of alpha-melanocyte-stimulating hormone, a 13-amino-acid neuropeptide produced mainly in the pituitary gland that the body uses as a natural brake on inflammation.

The appeal of KPV is that it keeps much of the anti-inflammatory activity of its parent hormone while shedding the pigmentation and other hormonal effects that alpha-MSH carries. Because it is so short, it is also more stable and easier to deliver than the full hormone, and small enough to survive passage through the gut in a way most peptides cannot. That combination of a clean anti-inflammatory signal and oral durability is why it draws interest for gut and skin research.

KPV reduces inflammation by quietening the master inflammatory switch inside cells rather than broadly shutting down the immune system. Its best-characterised action is suppression of NF-kappaB, the transcription factor that drives production of pro-inflammatory cytokines such as TNF-alpha, IL-6 and IL-1beta, along with inhibition of MAP kinase signalling.

The PepT1 route into cells

A key insight from the research is how KPV gets inside cells. In the gut it enters intestinal epithelial cells and immune cells through PepT1, the same transporter that absorbs small dietary peptides. This matters because PepT1 is over-expressed in inflamed colon tissue during inflammatory bowel disease, so KPV is naturally drawn toward the very tissue that is inflamed. Once inside, it dampens the inflammatory cascade at the source.

Receptor-dependent and receptor-independent effects

KPV is unusual in that much of its gut activity appears to work independently of the classical melanocortin receptors that its parent hormone uses, relying instead on this intracellular PepT1 route. In skin and other tissues, however, melanocortin receptors such as MC1R and MC3R do appear to play a supporting role. The practical effect across tissues is the same: lower cytokine output, reduced reactive oxygen species and more controlled immune-cell migration to sites of injury, without the blanket immunosuppression of corticosteroids.

KPV has a substantial preclinical record in cell and animal models of inflammation, but no completed human clinical trials, so every claim about it should be read as laboratory or animal evidence rather than proven human therapy.

Study / area	Evidence tier	Finding
Dalmasso et al. 2008	Cell + mouse colitis	Oral KPV reduced DSS and TNBS colitis severity
Kannengiesser et al. 2008	Mouse IBD models	Anti-inflammatory in two distinct colitis models
Dalmasso et al. 2011	Mouse model	Reduced colitis-associated tumours; effect lost in PepT1 knockouts
Xiao et al. 2017	Mouse, nanoparticle delivery	Targeted nanoparticles eased ulcerative colitis
Skin / wound models	In vitro + animal	Reduced redness and swelling, faster epithelial closure
Human use	None completed	No published controlled human trials to date

Gut inflammation

The landmark paper is by Guillaume Dalmasso and colleagues, published in Gastroenterology in 2008, which showed that nanomolar concentrations of KPV suppressed NF-kappaB and MAP kinase signalling in human intestinal and immune cells, and that oral KPV added to drinking water reduced the severity of both DSS-induced and TNBS-induced colitis in mice. The fact that it worked at such low concentrations and by the oral route is what made it stand out among anti-inflammatory peptides. A later 2017 study in Molecular Therapy from Bo Xiao and colleagues loaded KPV into hyaluronic-acid-functionalised nanoparticles roughly 272 nanometres across to target it specifically to inflamed colon tissue, easing ulcerative colitis in mice.

Skin and wound healing

In skin research, topical KPV has been reported in cell and animal studies to reduce inflammatory cytokines and chemokines, limit immune-cell migration into irritated tissue, speed up the resolution of inflammation and improve wound closure. These properties are why it is studied for inflammatory skin conditions such as eczema, dermatitis and burns, and they are the basis on which the FDA is reviewing it for a wound-healing indication.

KPV is not approved as a drug in any country and is not lawfully available for human use through compounding, but in the United States it is at an unusually active moment. The interim category system that governs compounding is set out in our explainer on the FDA’s interim category system.

Jurisdiction	Status	Notes
United States	Under review	On the July 2026 PCAC docket for the 503A bulks list
United Kingdom	Not approved	Research-chemical market only; no UK compounding pathway exists
Australia	Not approved	No TGA listing for KPV; supplied research-use only

Following the wider peptide reclassification of early 2026, the FDA’s April action removed KPV from the restricted Category 2 list and placed it among seven peptides scheduled for the Pharmacy Compounding Advisory Committee meeting on July 23 to 24, 2026 at the agency’s White Oak campus. KPV is grouped on the Day 1 agenda alongside BPC-157, TB-500 and MOTS-c, and the indications under review across that meeting range from ulcerative colitis and wound healing to several neurological uses. The agenda, deadlines and possible outcomes are detailed in our breakdown of the upcoming PCAC meeting, and the reclassification that produced this docket is set out in the 2026 reclassification timeline.

Outside the US, the position is simpler and more restrictive. The broad national context is set out in the US legal overview, with Britain covered in our look at the UK framework and Australia in our guide to the Australian position.

In the research that exists, KPV has a reassuring safety profile. It is a fragment of a hormone the body makes naturally, it is short, biodegradable and does not appear to accumulate in tissue, and reported adverse effects are minimal, mostly limited to mild injection-site reactions in subcutaneous studies. The honest caveat is that long-term human safety data simply does not exist, because the human trials have not been run.

Because KPV is a simple three-amino-acid peptide that is cheap and easy to synthesise, the practical risk in the research-chemical market is less about exotic impurities and more about underfilled, degraded or mislabelled vials, where a buyer has no way to confirm that what is in the vial matches the label. Verifying identity and content through independent testing is the only real safeguard, which is why we cover how to vet a peptide supplier and the practical skill of reading a certificate of analysis.

KPV is most often discussed alongside the other peptides marketed for recovery and repair, although its anti-inflammatory mechanism is distinct from the tissue-repair signalling of the better-known options. For the full category and how these compounds compare, see our recovery-peptide hub. The two repair peptides sharing KPV’s review date are covered in our BPC-157 write-up and our TB-500 write-up.